Treating aggressive blood cancer is hard. New options matter. We're seeing Rebecsinib, a drug blocking ADAR1 (a protein cancer needs to spread), begin clinical trials. First patient just received it. Even tested in space, this is measured progress.
Rebecsinib Clinical Trial Means New Options for Blood CancerResearchers at UC San Diego are advancing a new drug, Rebecsinib, into clinical trials for aggressive blood cancers. This innovative drug works by blocking the activation of a protein called ADAR1, whtoday.ucsd.edu